Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platform

该交易使公司能够推进由Prana专有的INSPIRE平台赋能的下一代、半衰期延长的多特异性抗体管线

PRA-216 is a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development for asthma, COPD, and atopic dermatitis, with a Phase 2 study in EoE planned; patient data from all four trials expected beginning in the second quarter of 2027

PRA-216 是一种新型 IL-4Rα/TSLP 双特异性抗体，目前正处于针对哮喘、慢性阻塞性肺病（COPD）和特应性皮炎的二期开发阶段，并计划开展针对嗜酸性粒细胞性食管炎（EoE）的二期研究；预计所有四项试验的患者数据将于 2027 年第二季度起陆续公布。

Concurrent private placement of $120 million in upfront financing with the potential to receive up to an additional $60 million upon exercise of accompanying warrants secured from leading healthcare institutional investors is expected to fund operations into 2028

与领先的医疗保健机构投资者达成的1.2亿美元前期融资的同步私募配售，以及在行使附随权证后有望额外获得高达6,000万美元的资金，预计将为公司的运营提供资金至2028年。

Following the transaction, Sheila Gujrathi, M.D., Prana’s Co-Founder and former Chief Executive Officer, will join Bolt’s executive team and Bolt’s Board of Directors

交易完成后，Prana 的联合创始人兼前任首席执行官 Sheila Gujrathi 博士将加入 Bolt 的高管团队及董事会。

Bolt to host conference call and webcast on October 26, 2026 at 8:30 a.m. ET

Bolt 将于2026年10月26日上午8:30（美国东部时间）主持电话会议和网络直播

REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”) today announced the acquisition of Prana Therapies, Inc. (“Prana”), a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies.

加利福尼亚州雷德伍德城，2026年10月23日（环球电讯社）——Bolt Biotherapeutics, Inc.（纳斯达克股票代码：BOLT）（“Bolt”或“公司”）今日宣布收购Prana Therapies, Inc.（“Prana”），这是一家处于临床阶段的生物技术公司，致力于开创下一代半衰期延长的多特异性抗体，旨在提供同类最佳的治疗方案。

Following the acquisition, the Company will focus on advancing Prana’s pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis (EoE) planned..

收购完成后，公司将专注于推进Prana基于其专有INSPIRE平台开发的半衰期延长型多特异性抗体管线，由PRA-216领衔。PRA-216是一种新型IL-4Rα/TSLP双特异性抗体，目前正处于针对哮喘、慢性阻塞性肺病（COPD）和特应性皮炎的II期开发阶段，并计划开展针对嗜酸性粒细胞性食管炎（EoE）的II期研究。

The acquisition was structured as a sign-and-close reverse merger, in which the parties entered into a merger agreement for a stock-for-stock transaction. Concurrent with the acquisition, Bolt entered into a securities purchase agreement for a private placement financing, which includes $120 million in upfront gross proceeds for the purchase of shares of Series D non-voting convertible preferred stock and up to an additional $60 million upon exercise of accompanying warrants with a syndicate of new and existing leading healthcare institutional investors, including Deep Track Capital, ADAR1 Capital, Andreessen Horowitz (a16z), LYFE Capital, Coastlands Capital, Eventide Asset Management, Casdin Capital, Curie.Bio, SilverArc Capital, Soleus Capital, Deviation Capital and other institutional investors.

本次收购采用“签约即交割”的反向合并架构，各方就一项换股交易签署了合并协议。与此同时，Bolt 就一次私募配售融资签订了证券购买协议，该融资包括来自新一批及现有领先医疗保健机构投资者的1.2亿美元前期总收益，用于购买D系列无投票权可转换优先股，以及在行使附随认股权证时最多额外获得的6,000万美元。参与的投资机构包括Deep Track Capital、ADAR1 Capital、Andreessen Horowitz（a16z）、LYFE Capital、Coastlands Capital、Eventide Asset Management、Casdin Capital、Curie.Bio、SilverArc Capital、Soleus Capital、Deviation Capital及其他机构投资者。

The proceeds from the private placement are expected to fund operations into 2028 and through multiple anticipated clinical and preclinical milestones..

预计私募所得资金将支持公司运营至2028年，并覆盖多个预期的临床及临床前里程碑。

“We built the INSPIRE platform to realize the potential of multispecific antibodies as medicines, combining complementary biology with the properties needed to deliver both greater efficacy and a better treatment experience for patients. PRA-216 is our flagship program, designed for best-in-disease efficacy together with the convenience of infrequent, at-home dosing,” said Sheila Gujrathi, M.D., Co-Founder and former Chief Executive Officer of Prana, and newly appointed Chief Strategy Officer.

“我们构建了INSPIRE平台，以释放多特异性抗体作为药物的潜力，将互补的生物学机制与实现更高疗效和更佳患者治疗体验所需的特性相结合。PRA-216是我们的旗舰项目，旨在提供同类最佳疾病疗效，同时具备居家低频给药的便利性。”Prana联合创始人兼前任首席执行官、新任首席战略官Sheila Gujrathi医学博士表示。

“This transaction and financing provide the resources to advance PRA-216 through multiple Phase 2 readouts in 2027 while continuing to expand our INSPIRE pipeline. We are grateful for the support of our new and existing investors as we enter this next stage of development.”.

“此次交易和融资为我们提供了资源，以推动PRA-216在2027年完成多项二期临床数据读出，同时继续扩展我们的INSPIRE产品管线。我们感谢新老投资者在我们进入这一新发展阶段时给予的支持。”

“We believe the acquisition of Prana provides a compelling opportunity for Bolt stockholders to participate in the potential of a differentiated, clinical-stage pipeline addressing large markets, beginning in inflammatory disease,” said Willie Quinn, Chief Executive Officer of Bolt Biotherapeutics. “We have been impressed by Prana’s team, the clinical profile demonstrated by PRA-216 to date, and the broader potential of the INSPIRE platform.

Bolt Biotherapeutics 首席执行官 Willie Quinn 表示：“我们相信，收购 Prana 为 Bolt 的股东提供了一个极具吸引力的机会，使其能够参与一个差异化的、处于临床阶段的管线所蕴含的潜力，该管线面向广阔的市场，并从炎症性疾病领域起步。Prana 的团队、PRA-216 迄今为止展现出的临床概况，以及 INSPIRE 平台更广泛的潜力，都给我们留下了深刻印象。”

We look forward to the opportunities ahead for the company.”.

我们期待公司未来的发展机遇。

Prana’s Pipeline Overview and Development Milestones

Prana 的管线概览与开发里程碑

Prana’s focus is to develop the next generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. The lead program, PRA-216, is a fully human, half-life-extended bispecific antibody targeting IL-4Rα and TSLP and is the first clinical program generated from Prana’s proprietary INSPIRE platform.

Prana 的焦点是开发下一代半衰期延长的多特异性抗体，旨在提供针对特定疾病的最佳疗法。其领先项目 PRA-216 是一种全人源、半衰期延长的双特异性抗体，靶向 IL-4Rα 和 TSLP，并且是基于 Prana 专有 INSPIRE 平台生成的首个临床项目。

PRA-216 combines broad downstream blockade of both IL-4 and IL-13 signaling (through IL-4Rα blockade) with upstream TSLP inhibition to address complementary drivers of inflammation..

PRA-216 通过阻断 IL-4Rα 来广泛抑制 IL-4 和 IL-13 信号通路的下游传导，并结合上游 TSLP 抑制作用，以应对炎症的互补驱动因素。

Prana disclosed data from the Phase 1 healthy volunteer study of PRA-216 as a late-breaking abstract at the 2026 European Respiratory Society. PRA-216 was well tolerated and demonstrated rapid, deep, and durable pharmacodynamic activity across multiple key Type 2 inflammatory biomarkers including pSTAT6, serum TARC, blood eosinophils, and IgE.

Prana在2026年欧洲呼吸学会会议上以最新突破摘要的形式公布了PRA-216在健康志愿者中进行的I期临床研究数据。PRA-216耐受性良好，并在包括pSTAT6、血清TARC、血液嗜酸性粒细胞和IgE在内的多个关键2型炎症生物标志物上展现出快速、深入且持久的药效学活性。

PRA-216 also demonstrated bioavailability and extended exposure supporting the potential for convenient, at-home maintenance dosing every eight to 12 weeks. Phase 2 development in asthma, COPD, and atopic dermatitis has been initiated, with a Phase 2 study in EoE planned, and with patient data from all four trials expected beginning in the second quarter of 2027 and continuing through the fourth quarter of 2027..

PRA-216还显示出良好的生物利用度和延长的暴露时间，支持每8至12周进行一次便捷的居家维持给药的潜力。已在哮喘、慢性阻塞性肺疾病（COPD）和特应性皮炎中启动II期开发，并计划开展嗜酸性粒细胞性食管炎（EoE）的II期研究。预计所有四项试验的患者数据将从2027年第二季度开始陆续公布，并持续至2027年第四季度。

PRA-216 provides the first clinical validation of Prana’s INSPIRE platform. INSPIRE continues to generate a pipeline of half-life-extended, fully IgG-based multispecific antibodies designed to overcome key limitations of conventional multispecific formats, including challenges with half-life, stability, manufacturability, immunogenicity, and subcutaneous delivery..

PRA-216 为 Prana 的 INSPIRE 平台提供了首个临床验证。INSPIRE 平台持续产生具有延长半衰期、完全基于 IgG 的多特异性抗体管线，旨在克服传统多特异性格式的关键局限性，包括半衰期、稳定性、可制造性、免疫原性以及皮下给药等方面的挑战。

Prana’s second program is an IL-31 containing bispecific antibody being developed initially for atopic dermatitis. First-in-human studies in healthy volunteers and patients are expected to begin in the second half of 2027, with clinical data also expected in the second half of 2027.

Prana的第二个项目是一种含IL-31的双特异性抗体，最初针对特应性皮炎开发。预计将于2027年下半年在健康志愿者和患者中启动首次人体研究，并有望在同一时期获得临床数据。

Two additional undisclosed pipeline programs are expected to advance toward IND-enabling development by the second half of 2027.

预计到2027年下半年，另外两个未公开的管线项目将推进至支持新药临床试验申请（IND）的开发阶段。

About the Transactions

关于交易

The acquisition was structured as a stock-for-stock transaction via sign-and-close reverse merger, pursuant to which all outstanding equity interests of Prana were exchanged based on a fixed exchange ratio for a combination of 430,746 shares of Bolt common stock and 16,360.929 shares of Series D non-voting convertible preferred stock (representing 16,791,675 shares of Bolt common stock on an as-converted-to-common basis and without giving effect to any beneficial ownership limitations)..

本次收购采用通过“签约即交割”的反向合并方式进行的换股交易结构，据此，Prana的所有未偿股权权益按照固定兑换比率被置换为430,746股Bolt普通股和16,360.929股D系列无投票权可转换优先股的组合（按转换为普通股的基础计算，相当于16,791,675股Bolt普通股，且未考虑任何实益所有权限制）。

Concurrent with the acquisition, Bolt entered into a definitive agreement for a private placement financing to raise $120 million in gross proceeds, for the purchase of 13,995.311 shares of Series D non-voting convertible preferred stock (or 13,995,311 shares of Bolt common stock on an as-converted-to-common basis and without giving effect to any beneficial ownership limitations) at a price of $8,574.30 per share (or $8.5743 per share on an as-converted basis) and up to an additional $60 million upon exercise of accompanying warrants to purchase up to 6,997,655 shares of common stock (or shares of Series D non-voting convertible preferred stock under certain circumstances), in each case at an exercise price of $8,574.30 per Series D share (or $8.5743 per share on an as-converted basis), in each case as described below.

与此次收购同步，Bolt 签订了一份私募融资的最终协议，以筹集总额为 1.2 亿美元的资金，用于以每股 8,574.30 美元（或按转换为普通股基础计算的每股 8.5743 美元）的价格购买 13,995.311 股 D 系列无投票权可转换优先股（或在转换为普通股基础上且不考虑任何受益所有权限制的情况下相当于 13,995,311 股 Bolt 普通股）。此外，通过行使随附的认股权证，公司还可额外筹集高达 6,000 万美元，该等认股权证可用于购买最多 6,997,655 股普通股（或在某些情况下为 D 系列无投票权可转换优先股），在每种情况下，行权价格均为每股 D 系列股份 8,574.30 美元（或按转换为普通股基础计算的每股 8.5743 美元），具体情况如下所述。

The private placement is expected to close on October 26, 2026..

预计此次非公开发行将于2026年10月26日完成交割。

Subject to Bolt stockholder approval in accordance with Nasdaq listing rules, each share of Series D non-voting convertible preferred stock will automatically convert into 1,000 shares of Bolt common stock, subject to certain beneficial ownership limitations set by each holder, and after conversion, each warrant will then become exercisable for shares of common stock, subject to certain beneficial ownership limitations set by each holder..

在获得Bolt股东根据纳斯达克上市规则批准的前提下，每股D系列无投票权可转换优先股将自动转换为1,000股Bolt普通股，但须受各持有人设定的某些实益所有权限制约束；转换后，每份认股权证将可行使为普通股股份，同样须受各持有人设定的某些实益所有权限制约束。

The acquisition was approved by the Board of Directors of Bolt and the Board of Directors and stockholders of Prana. The closings of the acquisition and the private placement were not subject to the approval of Bolt’s stockholders. The approval of Bolt’s stockholders is required, among other things, under the terms of the Series D non-voting convertible preferred stock in order for the Series D non-voting convertible preferred stock to be converted into shares of Bolt’s common stock, and Bolt is required to hold a stockholder meeting for such vote.

该收购已获得Bolt董事会以及Prana董事会和股东的批准。此次收购及私募配售的交割无需经过Bolt股东的批准。然而，根据D系列无投票权可转换优先股的条款，要将该系列优先股转换为Bolt普通股股份，除其他事项外，必须获得Bolt股东的批准，因此Bolt需召开股东会议就此进行表决。

The warrants issuable upon closing of the private placement will become exercisable for cash to purchase shares of common stock upon the automatic conversion of the Series D non-voting convertible preferred stock into common stock following receipt of the requisite stockholder approval (or shares of Series D non-voting convertible preferred stock under certain circumstances), at the applicable exercise price specified therein.

在获得必要的股东批准后，D系列无投票权可转换优先股将自动转换为普通股（或在某些情况下转换为D系列无投票权可转换优先股），届时，因私募交割而发行的认股权证将可按其中规定的适用行权价格以现金行权，购买普通股股份。

The warrants will expire on the earlier of (i) 30 days following the company’s first public disclosure of top-line results from the first-in-human clinical data from its Program 2 Phase 1 (IL-31 bispecific), such disclosure to include at least two dosing cohorts from subjects administered subcutaneous single ascending doses (n = approximately 8 per group) with at least 8 weeks post-dose follow up, similar to Phase 1 data previously generated for PRA-216 and (ii) June 30, 2028..

认股权证将在以下较早日期到期：(i) 公司首次公开披露其项目2第一阶段（IL-31双特异性抗体）的首次人体临床试验的顶层结果后30天，该披露须包括至少两个接受皮下单次递增剂量给药（每组约8名受试者）的剂量队列，且给药后随访时间至少为8周，类似于此前为PRA-216生成的第一阶段数据；以及(ii) 2028年6月30日。

As a result of the transactions, equity holders of Bolt immediately prior to the acquisition will own approximately 6.9% of Bolt’s common stock, equity holders of Prana immediately prior to the acquisition will own approximately 51.7% of Bolt common stock and investors in the private placement financing will own approximately 41.4% of Bolt common stock, in each case, calculated on a fully-diluted basis (without giving effect to any beneficial ownership limitations and assuming the conversion in full of the Series D non-voting convertible preferred stock into common stock) using the treasury stock method and based on the implied equity values of Bolt and Prana.

作为交易的结果，在收购完成前立即持有Bolt股权的股东将拥有Bolt普通股约6.9%的股份，在收购完成前立即持有Prana股权的股东将拥有Bolt普通股约51.7%的股份，而参与私募配售融资的投资者将拥有Bolt普通股约41.4%的股份。上述持股比例均按完全稀释基础计算（不考虑任何实益所有权限制，并假设D系列无投票权可转换优先股全部转换为普通股），采用库藏股法，并基于Bolt和Prana的隐含股权价值。

On an as-converted basis and after accounting for these transactions (and without giving effect to any beneficial ownership limitations), the total number of shares of Bolt common stock (including shares underlying the Series D non-voting convertible preferred stock) will be approximately 34,183,982..

在完全转换的基础上，并考虑这些交易的影响（且不考虑任何实益所有权限制），Bolt 普通股（包括 D 系列无投票权可转换优先股所对应的股份）的总股数将约为 34,183,982 股。

Following receipt of the $120 million in upfront gross proceeds from the private placement, Bolt is expected to have projected cash runway into 2028.

在收到来自私募配售的1.2亿美元前期总收益后，Bolt预计其现金跑道将延伸至2028年。

Management and Board of Directors

管理层与董事会

In connection with the closing of the merger, Sheila Gujrathi, M.D., Prana’s Co-Founder and former Chief Executive Officer, has been appointed Chief Strategy Officer of Bolt and has joined the Bolt Board of Directors.

随着合并交易的完成，Prana 的联合创始人兼前首席执行官希拉·古吉拉蒂（Sheila Gujrathi）医学博士已被任命为 Bolt 的首席战略官，并加入 Bolt 董事会。

Advisory and Legal Counsel

顾问及法律顾问

Jefferies LLC, TD Cowen, Stifel, and LifeSci Capital are serving as placement agents for the concurrent private placement financing. Tungsten Advisors is also serving as financial advisor and placement agent to Prana. Cooley LLP is serving as legal counsel to Prana. Sidley Austin LLP is serving as legal counsel to Bolt.

杰富瑞有限责任公司（Jefferies LLC）、TD Cowen、Stifel 和 LifeSci Capital 担任此次同步私募配售融资的配售代理。Tungsten Advisors 同时担任 Prana 的财务顾问及配售代理。Cooley LLP 担任 Prana 的法律顾问。Sidley Austin LLP 担任 Bolt 的法律顾问。

Lake Street Capital Markets provided a fairness opinion to Bolt’s Board of Directors. Gibson, Dunn & Crutcher LLP is serving as legal counsel to the placement agents..

Lake Street Capital Markets 向 Bolt 董事会提供了公平性意见。Gibson, Dunn & Crutcher LLP 担任配售代理的法律顾问。

Conference Call and Webcast

电话会议和网络直播

Bolt will host a conference call and webcast on Monday, October 26, 2026 at 8:30 a.m. ET to discuss the transaction, financing, and the company’s pipeline.

Bolt 将于 2026 年 10 月 26 日（星期一）美国东部时间上午 8:30 举行电话会议和网络直播，讨论此次交易、融资以及公司的产品管线。

To listen to the live webcast, or access the archived webcast and accompanying presentation, please visit: https://investors.boltbio.com/news-and-events/events-and-presentations. Following the live webcast, a replay will be available on Bolt’s website.

如需收听网络直播，或访问存档的网络直播及随附演示文稿，请访问：https://investors.boltbio.com/news-and-events/events-and-presentations。直播结束后，重播将在 Bolt 网站上提供。

About Bolt Biotherapeutics, Inc.

关于 Bolt Biotherapeutics 公司

Bolt Biotherapeutics is a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Through the proprietary INSPIRE platform it acquired from Prana Therapies, the company combines complementary therapeutic mechanisms in fully IgG-based molecules designed for differentiated efficacy, extended exposure, and convenient dosing..

Bolt Biotherapeutics 是一家处于临床阶段的生物技术公司，正在开创新一代半衰期延长的多特异性抗体，旨在提供同类最佳疾病治疗方案。通过从 Prana Therapies 收购的专有 INSPIRE 平台，该公司将互补的治疗机制结合于完全基于 IgG 的分子中，旨在实现差异化的疗效、延长的暴露时间和便捷的给药方案。

The company’s lead program, PRA-216, is a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease, and atopic dermatitis, with a fourth Phase 2 study planned in eosinophilic esophagitis. In addition to PRA-216, Bolt Biotherapeutics is advancing a wholly owned pipeline of additional INSPIRE-based multispecific programs across diseases with significant unmet need..

公司的领先项目 PRA-216 是一种新型 IL-4Rα/TSLP 双特异性抗体，目前正处于针对哮喘、慢性阻塞性肺病和特应性皮炎的二期开发阶段，并计划开展第四项针对嗜酸性粒细胞性食管炎的二期研究。除了 PRA-216 之外，Bolt Biotherapeutics 正在推进其完全自主拥有的基于 INSPIRE 平台的多特异性项目管线，涵盖存在重大未满足医疗需求的多种疾病领域。

For more information, please visit https://www.boltbio.com/.

更多信息，请访问 https://www.boltbio.com/。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including, without limitation, statements regarding Bolt, Prana, the concurrent private placement financing and the acquisition of Prana by Bolt (the “Transactions”) and other matters, including, without limitation, statements regarding: the Transactions, including the closing of the concurrent private placement financing, including any additional gross proceeds that may be received upon exercise, if any, of accompanying warrants, if any, and the expected effects, perceived benefits or opportunities and related timing with respect thereto; expectations regarding or plans for the company’s pipeline, including its ongoing and planned clinical trials, research and development programs and the expected timing for key milestones, including the release of clinical data; the potential benefits of PRA-216 and Prana’s other clinical programs; and expectations regarding the use of proceeds from the concurrent private placement financing and cash runway expectations therefrom, including such proceeds funding the company through key clinical milestones; and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

本新闻稿包含有关我们及我们行业的前瞻性陈述，这些陈述涉及重大风险和不确定性，并基于我们的信念和假设以及目前向我们提供的信息。除本新闻稿中包含的历史事实陈述外，所有其他陈述均为前瞻性陈述，包括但不限于关于Bolt、Prana、同步进行的私募配售融资以及Bolt收购Prana（统称“交易”）和其他事项的陈述，包括（但不限于）以下方面的陈述：交易，包括同步私募配售融资的完成，包括在行使任何随附认股权证（如有）时可能获得的任何额外毛收益，以及与此相关的预期影响、感知利益或机会和相关时间安排；对公司产品管线的预期或计划，包括其正在进行的和计划中的临床试验、研发项目以及关键里程碑（包括临床数据的发布）的预期时间安排；PRA-216和Prana其他临床项目的潜在益处；以及对同步私募配售融资所得款项用途的预期及由此产生的现金跑道预期，包括此类所得款项为公司提供资金直至实现关键临床里程碑；以及任何提及对未来事件或情况的预测、预估或其他描述的陈述（包括任何基础假设），均属于前瞻性陈述。

In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or .

在某些情况下，您可以通过识别其中包含的“anticipate”（预期）、“believe”（相信）、“could”（可能）、“estimate”（估计）、“expect”（期望）、“intend”（打算）、“may”（或许）、“on track”（进展顺利）、“plan”（计划）、“potential”（潜在）、“predict”（预测）、“project”（规划）、“should”（应当）、“will”（将）等词语来辨别前瞻性陈述。

Contacts

联系人

Christina Trout

克里斯蒂娜·特劳特

VP, Corporate Development

企业发展副总裁

investors@pranatherapies.com

investors@pranatherapies.com

Matthew DeYoung

马修·德扬

Argot Partners

阿戈特合伙公司

(212) 600-1902

(212) 600-1902

boltbio@argotpartners.com

boltbio@argotpartners.com